Background/aim: The importance of compliance with National Comprehensive Cancer Network (NCCN) guidelines for preventing varicella-zoster virus reactivation (VZVr) in multiple myeloma (MM) in a clinical setting has not been well investigated.
Patients And Methods: We retrospectively studied the clinical characteristics and outcomes of 118 patients with MM treated with proteasome inhibitors.
Results: Thirty-nine episodes of VZVr were observed in 37 patients (VZVr group).
The instability of pharmaceutical monoclonal antibodies are affected by physical stimuli including, temperature, denaturant, surfactant, stirring, solid phase adsorption, oxidation, and ultraviolet rays. Clinically, we frequently experience precipitation during preparation of several pharmaceutical monoclonal antibodies for cancer. Although it is possible to remove precipitates in the injection solution during the preparation procedure, potential filter blockade during administration remains a problem with adverse effects on the quality of life of patients.
View Article and Find Full Text PDF